Tags

Type your tag names separated by a space and hit enter

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Int J Antimicrob Agents. 2018 Feb; 51(2):181-189.IJ

Abstract

The aim of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae and Pseudomonas aeruginosa isolates from patients in the Asia-Pacific (APAC) region with healthcare-associated infections. Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 1963 Gram-negative organisms (489 P. aeruginosa and 1474 Enterobacteriaceae) were consecutively collected using a prevalence-based approach from 14 medical centres in the APAC region. Antimicrobial susceptibility testing was performed by broth microdilution method as described by the CLSI and the results were interpreted according to EUCAST and CLSI breakpoint criteria. Ceftolozane/tazobactam [MIC50/90, 0.25/4 µg/mL; 89.2/85.8% susceptible (CLSI/EUCAST)] and meropenem [MIC50/90, ≤0.06/≤0.06 µg/mL; 96.3/96.5% susceptible (CLSI/EUCAST)] were the most active compounds tested against Enterobacteriaceae. Isolates displayed susceptibility rates to other β-lactam agents ranging from 85.8/81.0% for piperacillin/tazobactam to 74.4/72.7% for cefepime and 72.8/68.1% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates, 3.6% were carbapenem-resistant Enterobacteriaceae (CRE) and 25.6% exhibited an extended-spectrum β-lactamase (ESBL) non-CRE phenotype. Ceftolozane/tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/16 µg/mL), but not against isolates with a CRE phenotype (MIC50/90, >32/>32 µg/mL). Ceftolozane/tazobactam was the most potent (MIC50/90, 0.5/4 µg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 90.8% at an MIC of ≤4 µg/mL. Pseudomonas aeruginosa exhibited high rates of susceptibility to amikacin [91.2/89.4% (CLSI/EUCAST)] and colistin [98.4/100.0% (CLSI/EUCAST)]. Ceftolozane/tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins when tested against Enterobacteriaceae.

Authors+Show Affiliations

JMI Laboratories, North Liberty, Iowa, USA; University of Iowa College of Medicine, Iowa City, Iowa, USA. Electronic address: mike-pfaller@jmilabs.com.JMI Laboratories, North Liberty, Iowa, USA.JMI Laboratories, North Liberty, Iowa, USA.JMI Laboratories, North Liberty, Iowa, USA.JMI Laboratories, North Liberty, Iowa, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28993143

Citation

Pfaller, M A., et al. "Ceftolozane/tazobactam Activity Against Drug-resistant Enterobacteriaceae and Pseudomonas Aeruginosa Causing Healthcare-associated Infections in the Asia-Pacific Region (minus China, Australia and New Zealand): Report From an Antimicrobial Surveillance Programme (2013-2015)." International Journal of Antimicrobial Agents, vol. 51, no. 2, 2018, pp. 181-189.
Pfaller MA, Shortridge D, Sader HS, et al. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Int J Antimicrob Agents. 2018;51(2):181-189.
Pfaller, M. A., Shortridge, D., Sader, H. S., Castanheira, M., & Flamm, R. K. (2018). Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). International Journal of Antimicrobial Agents, 51(2), 181-189. https://doi.org/10.1016/j.ijantimicag.2017.09.016
Pfaller MA, et al. Ceftolozane/tazobactam Activity Against Drug-resistant Enterobacteriaceae and Pseudomonas Aeruginosa Causing Healthcare-associated Infections in the Asia-Pacific Region (minus China, Australia and New Zealand): Report From an Antimicrobial Surveillance Programme (2013-2015). Int J Antimicrob Agents. 2018;51(2):181-189. PubMed PMID: 28993143.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). AU - Pfaller,M A, AU - Shortridge,D, AU - Sader,H S, AU - Castanheira,M, AU - Flamm,R K, Y1 - 2017/10/06/ PY - 2017/04/10/received PY - 2017/08/11/revised PY - 2017/09/30/accepted PY - 2017/10/11/pubmed PY - 2018/8/17/medline PY - 2017/10/11/entrez KW - Asia-Pacific KW - Ceftolozane/tazobactam KW - Drug resistance KW - Enterobacteriaceae KW - Pseudomonas aeruginosa KW - Surveillance SP - 181 EP - 189 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 51 IS - 2 N2 - The aim of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae and Pseudomonas aeruginosa isolates from patients in the Asia-Pacific (APAC) region with healthcare-associated infections. Ceftolozane/tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 1963 Gram-negative organisms (489 P. aeruginosa and 1474 Enterobacteriaceae) were consecutively collected using a prevalence-based approach from 14 medical centres in the APAC region. Antimicrobial susceptibility testing was performed by broth microdilution method as described by the CLSI and the results were interpreted according to EUCAST and CLSI breakpoint criteria. Ceftolozane/tazobactam [MIC50/90, 0.25/4 µg/mL; 89.2/85.8% susceptible (CLSI/EUCAST)] and meropenem [MIC50/90, ≤0.06/≤0.06 µg/mL; 96.3/96.5% susceptible (CLSI/EUCAST)] were the most active compounds tested against Enterobacteriaceae. Isolates displayed susceptibility rates to other β-lactam agents ranging from 85.8/81.0% for piperacillin/tazobactam to 74.4/72.7% for cefepime and 72.8/68.1% for ceftazidime using CLSI/EUCAST breakpoints. Among the Enterobacteriaceae isolates, 3.6% were carbapenem-resistant Enterobacteriaceae (CRE) and 25.6% exhibited an extended-spectrum β-lactamase (ESBL) non-CRE phenotype. Ceftolozane/tazobactam showed good activity against ESBL non-CRE phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/16 µg/mL), but not against isolates with a CRE phenotype (MIC50/90, >32/>32 µg/mL). Ceftolozane/tazobactam was the most potent (MIC50/90, 0.5/4 µg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 90.8% at an MIC of ≤4 µg/mL. Pseudomonas aeruginosa exhibited high rates of susceptibility to amikacin [91.2/89.4% (CLSI/EUCAST)] and colistin [98.4/100.0% (CLSI/EUCAST)]. Ceftolozane/tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins when tested against Enterobacteriaceae. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/28993143/Ceftolozane/tazobactam_activity_against_drug_resistant_Enterobacteriaceae_and_Pseudomonas_aeruginosa_causing_healthcare_associated_infections_in_the_Asia_Pacific_region__minus_China_Australia_and_New_Zealand_:_report_from_an_Antimicrobial_Surveillance_Programme__2013_2015__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-8579(17)30364-3 DB - PRIME DP - Unbound Medicine ER -